Semaglutide for obesity: four STEPs forward, but more to come

DH Ryan - The Lancet Diabetes & Endocrinology, 2021 - thelancet.com
Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …
被引用次数：11 相关文章

[引用][C] Semaglutide for obesity: four STEPs forward, but more to come

DH Ryan - The lancet. Diabetes & endocrinology, 2021 - pubmed.ncbi.nlm.nih.gov
Semaglutide for obesity: four STEPs forward, but more to come Semaglutide for obesity: four
STEPs forward, but more to come Lancet Diabetes Endocrinol. 2021 May;9(5):252-254. doi …

[引用][C] Semaglutide for obesity: four STEPs forward, but more to come.

DH Ryan - The lancet. Diabetes & Endocrinology, 2021 - europepmc.org
Semaglutide for obesity: four STEPs forward, but more to come. - Abstract - Europe PMC Sign in
| Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …

Semaglutide for obesity: four STEPs forward, but more to come

DH Ryan - The Lancet Diabetes & Endocrinology, 2021 - thelancet.com
Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …